农林牧渔/动物保健Ⅱ 科前生物（688526.SH） 归母净利润同比高增，新品持续推出创新驱动成长 2025 年 08 月 26 日 投资评级：买入（维持） 日期 2025/8/26 当前股价(元) 19.33 一年最高最低(元) 20.39/11.00 总市值(亿元) 90.10 流通市值(亿元) 90.10 总股本(亿股) 4.66 流通股本(亿股) 4.66 近 3 个月换手率(%) 48.32 股价走势图 -20% 0% 20% 40% 60% 80% 2024-08 2024-12 2025-04 2025-08 科前生物 沪深300 数据来源：聚源 相关研究报告 《经营韧性十足，创新驱动成长—公 司信息更新报告》-2025.4.30 《后周期业绩有望修复向上，新品持 续发力持续成长—公司信息更新报 告》-2024.11.3 《经营短期承压，静待 2024H2 业绩修 复—公司信息更新报告》-2024.9.1 陈雪丽（分析师） 王高展（分析师） chenxueli@kysec.cn 证书编号：S0790520030001 wanggaozhan@kysec.cn 证书编号：S079052507000 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company has shown better-than-expected performance with continuous product structure upgrades, maintaining a focus on marketing transformation and orderly adjustments in provincial markets [6][7] - For the first half of 2025, the company achieved total revenue of 1.759 billion yuan, a year-on-year increase of 0.3%, and a net profit attributable to the parent company of 298 million yuan, a year-on-year increase of 1.1% [6] - The company is adjusting its profit forecasts for 2025-2027, expecting net profits of 410 million yuan, 460 million yuan, and 540 million yuan respectively, with year-on-year growth rates of 4.6%, 13.1%, and 16.9% [6] Financial Performance - In Q2 2025, the company reported revenue of 651 million yuan, a year-on-year decrease of 4.0%, and a net profit of 64 million yuan, a year-on-year decrease of 12.8% [6] - The revenue breakdown for Q2 2025 shows that products priced above 300 yuan, between 100-300 yuan, and below 100 yuan generated revenues of 136 million yuan, 340 million yuan, and 145 million yuan respectively, with year-on-year changes of +11.3%, +0.3%, and -26.6% [7] - The company's cash flow performance is better than revenue, with cash sales of 749 million yuan in Q2 2025, a year-on-year increase of 17.2% [8] Profitability Metrics - The gross margin decreased by 1.0 percentage points in Q2 2025, primarily due to a slowdown in sales of products priced below 100 yuan after previous price increases [9] - The net profit margin in Q2 2025 decreased by 1 percentage point to 9.9% [9] - The company maintains a long-term trend of more precise and efficient expense allocation, with a sales expense ratio increasing by 1.6 percentage points year-on-year [9] Financial Summary and Valuation Indicators - For 2025, the expected revenue is 3.135 billion yuan, with a year-on-year growth of 3.8% [11] - The expected diluted EPS for 2025 is 0.80 yuan, with a corresponding P/E ratio of 26.6 times [11] - The expected net profit for 2025 is 406 million yuan, with a year-on-year growth of 4.6% [11]

Investment Rating - The investment rating for Qingdao Beer (600600) is maintained as "Buy" [6] Core Views - The report highlights that Qingdao Beer has achieved a revenue of 20.49 billion yuan in H1 2025, with a year-on-year growth of 2.11%, and a net profit attributable to shareholders of 3.90 billion yuan, reflecting a growth of 7.21% [6] - The company is expected to continue optimizing its product structure, with a forecasted net profit of 4.79 billion yuan in 2025, representing a year-on-year growth of 10.3% [6] - The report emphasizes the potential for profit margin improvement due to cost reductions in raw materials and an increase in the proportion of high-end products [6] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 33.50 billion yuan, with a year-on-year growth rate of 4.2% [2] - Net profit attributable to shareholders is projected to be 4.79 billion yuan in 2025, with a growth rate of 10.3% [2] - Earnings per share (EPS) is expected to be 3.51 yuan in 2025, with a projected PE ratio of 20 [2] Market Data - As of August 26, 2025, the closing price of Qingdao Beer is 69.78 yuan, with a market capitalization of 49.48 billion yuan [3] - The stock has a dividend yield of 3.15%, based on the most recent dividend announcement [3] - The price-to-book ratio is reported at 3.1 [3] Sales Performance - In Q2 2025, the company sold 2.471 million tons of beer, marking a 1% increase year-on-year, with a revenue per ton of 4,065.41 yuan, a slight increase of 0.3% [6] - The sales volume of the main brand and mid-to-high-end products increased by 3.8% and 4.81% respectively, with mid-to-high-end products accounting for 39.7% of total sales [6] Cost and Profitability - The cost per ton of beer in Q2 2025 was 2,201.88 yuan, a decrease of 5.1% year-on-year, contributing to a gross margin of 45.84%, an increase of 3.05 percentage points [6] - The net profit margin for Q2 2025 was 21.84%, reflecting a year-on-year increase of 1.23 percentage points [6]

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company's performance met expectations, with profit growth outpacing revenue growth. In H1 2025, total revenue reached 5.362 billion yuan (up 7.21% YoY), and net profit attributable to shareholders was 799 million yuan (up 13.80% YoY) [7] - The company is planning a Hong Kong stock listing to accelerate international development and enhance overseas financing capabilities [7] - The new management strategy has shown initial results, with over 10 new products launched in the first half of 2025, expanding into new categories such as whitening and medical beauty [7] Financial Summary - Total revenue projections for 2025 are estimated at 11.854 billion yuan, with a YoY growth rate of 10.0% [6] - The net profit attributable to shareholders is projected to be 1.756 billion yuan in 2025, reflecting a YoY growth rate of 13.1% [6] - The gross margin for H1 2025 was reported at 73.4%, an increase of 3.6 percentage points YoY, while the net profit margin was 15.4%, up 0.9 percentage points YoY [7]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Views - The company reported significant growth in its H1 2025 performance, with a revenue of 1197.58 billion yuan, representing a year-on-year increase of 32.99%. The net profit attributable to shareholders was 72.46 billion yuan, up 72.48%, and the net profit excluding non-recurring items was 66.61 billion yuan, reflecting a growth of 98.25% [6][2]. - The outlook for 2025 indicates continued growth in the high-speed train business, improvement in locomotive operations, and development in urban rail and new industries, suggesting a sustained upward trend in the company's operations [2][11]. Summary by Sections Financial Performance - In H1 2025, the company achieved a total revenue of 1197.58 billion yuan, a 32.99% increase year-on-year. The net profit attributable to shareholders was 72.46 billion yuan, marking a 72.48% increase, while the net profit excluding non-recurring items reached 66.61 billion yuan, up 98.25% [6][2]. - The railway equipment business generated revenue of 597 billion yuan, a 42% increase, driven by growth in high-speed trains and freight cars. Urban rail and city infrastructure revenue was 174 billion yuan, up 6%, and new industry revenue was 407 billion yuan, reflecting a 36% increase [11][11]. Profitability Metrics - The overall gross margin for H1 2025 was 21.81%, an increase of 0.40 percentage points year-on-year. The gross margins for railway equipment, urban rail, new industries, and modern services were 25.17%, 18.86%, 17.74%, and 30.86%, respectively [11][11]. - The net profit margin for H1 2025 was 7.45%, an increase of approximately 1.3 percentage points compared to H1 2024 [11]. Market Outlook - The railway passenger and freight transport sectors are experiencing high demand, with passenger volume reaching 2.691 billion, a 6.7% increase year-on-year. Freight transport also showed a positive trend, with 4.52 million tons transported in July, up 4.5% [11][11]. - The company is committed to international expansion, leveraging opportunities from the Belt and Road Initiative and enhancing its global market presence [11][11]. Dividend Policy - The company announced a mid-term cash dividend of 1.1 yuan per 10 shares, totaling 31.57 billion yuan, which represents 43.57% of the net profit attributable to shareholders for H1 2025 [11][11]. Future Projections - The company is expected to achieve net profits of 147 billion yuan and 164 billion yuan for 2025 and 2026, respectively, with corresponding price-to-earnings ratios of 15.0 and 13.4 [11][11].

Investment Rating - The investment rating for the company is "Accumulate" and is maintained [8] Core Views - In the first half of 2025, the company achieved operating revenue of 1.66 billion yuan, a year-on-year increase of 12.07%, and a net profit attributable to shareholders of 119 million yuan, a year-on-year increase of 42.54% [2][6] - The sales volume of new energy sanitation equipment drove revenue growth in the equipment business, while the investment income from the sale of sanitation service business significantly impacted current performance [2][12] - The company plans to focus on manufacturing new energy sanitation equipment and mining equipment after the divestiture of its sanitation service business, which is expected to enhance cash flow [12] Summary by Sections Financial Performance - In Q2 2025, the company achieved operating revenue of 953 million yuan, a year-on-year increase of 22.21%, and a net profit attributable to shareholders of 67 million yuan, a year-on-year increase of 30.27% [6] - The company’s overall revenue for the first half of 2025, excluding the impact of the sanitation service business, was approximately 1.493 billion yuan, a year-on-year increase of 29.69% [12] Business Segments - The sanitation equipment business generated revenue of 798 million yuan, a year-on-year increase of 34.34%, with sales volume of 1,287 units, down 8.01% [12] - The mining equipment segment achieved revenue of 641 million yuan, a year-on-year increase of 111.25%, with sales volume up 74.90% [12] - The company maintained a leading position in the industry despite increased competition affecting profit contributions [12] Strategic Moves - The transfer of 85% equity in the sanitation service subsidiary, Aolande, was completed in Q2, resulting in an investment income of 85 million yuan [12] - The divestiture is expected to allow the company to avoid competition with its sanitation equipment customers and focus on its core manufacturing strengths [12] Long-term Outlook - The company is viewed positively for its competitive advantages in integrated manufacturing capabilities, which are expected to drive long-term performance improvements [12] - Projected net profits for 2025-2027 are estimated at 280 million yuan, 380 million yuan, and 460 million yuan, respectively, with corresponding P/E ratios of 23x, 17x, and 14x [12]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - In the first half of 2025, the company achieved operating revenue of 3.904 billion yuan, a year-on-year decrease of 5.1%, while the net profit attributable to shareholders was 1.425 billion yuan, a slight increase of 0.13% [2][6]. - The environmental protection business continues to grow steadily, with the equipment and EPC segments experiencing a decline due to the revenue recognition schedule [11]. - The cash flow has shown continuous improvement, and the new energy materials project has commenced trial production, indicating potential for future revenue growth [11]. Summary by Sections Financial Performance - For Q2 2025, the company reported operating revenue of 1.894 billion yuan, down 10.04% year-on-year, and a net profit of 709 million yuan, down 0.24% [2][6]. - The company’s total revenue for the first half of 2025 was 3.904 billion yuan, with a gross profit margin of 49.0%, an increase of 3.3 percentage points year-on-year [11]. Business Segments - The company’s waste incineration projects processed 6.8932 million tons of waste in the first half of 2025, with a year-on-year increase of 8.71%, contributing to an environmental operation revenue of 1.711 billion yuan, up 6.2% [11]. - The equipment manufacturing and service segment saw new orders of 3.559 billion yuan, a significant increase compared to 1.213 billion yuan in the same period last year, although revenue from this segment decreased by 12.5% [11]. New Energy Materials - The company’s new energy materials project has begun trial production, with the production of 2,306 tons of nickel-containing products in the first half of 2025 [11]. - The company is actively expanding its lithium battery material production capacity and has invested in a lithium carbonate project in Fujian [11]. Future Outlook - The company expects net profits attributable to shareholders to reach 2.96 billion yuan, 3.47 billion yuan, and 3.97 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 11.2x, 9.6x, and 8.3x [11].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company achieved total revenue of 7.534 billion yuan in H1 2025, representing a year-on-year increase of 18.04%. The net profit attributable to shareholders was 307 million yuan, up 27.76% year-on-year, and the net profit after deducting non-recurring gains and losses was 291 million yuan, an increase of 32.24% year-on-year [2][4]. - In Q2 2025, the company reported revenue of 4.557 billion yuan, a year-on-year increase of 47.8% and a quarter-on-quarter increase of 53%. The net profit attributable to shareholders was 190 million yuan, up 48% year-on-year, and the net profit after deducting non-recurring gains and losses was 179 million yuan, an increase of 53% year-on-year [2][4]. - The company sold 28,800 tons of lithium cobalt oxide, a year-on-year increase of 56.64%. The sales of power cathode materials (including ternary materials and lithium iron phosphate) reached 31,900 tons, up 20.76% year-on-year. In the hydrogen energy materials segment, sales were 1,974.61 tons, an increase of 6.16% year-on-year [10]. - The company is expected to maintain positive growth in sales, benefiting from differentiated competition in high-voltage and high-power ternary materials and hydrothermal lithium iron phosphate [10]. Summary by Sections Financial Performance - In H1 2025, the company achieved total revenue of 7.534 billion yuan, with a net profit of 307 million yuan and a net profit after deducting non-recurring gains and losses of 291 million yuan [2][4]. - For Q2 2025, revenue was 4.557 billion yuan, with a net profit of 190 million yuan and a net profit after deducting non-recurring gains and losses of 179 million yuan [2][4]. Sales and Market Position - The company sold 28,800 tons of lithium cobalt oxide, 31,900 tons of power cathode materials, and 1,974.61 tons of hydrogen energy materials, indicating strong market demand and a solid industry position [10]. - The company is expected to benefit from the rising cobalt prices, which may further enhance profitability [10]. Future Outlook - The traditional business is expected to see growth due to increased market share and production rates, with a focus on AI applications driving product premium [10]. - New products in the NL cathode materials segment are progressing well, with positive feedback from downstream manufacturers [10]. - The company is well-positioned in the solid-state battery segment, with ongoing developments in lithium sulfide electrolytes and oxide solid-state electrolytes [10].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark within the next six months [18]. Core Views - The company reported a revenue of 3.11 billion yuan for the first half of 2025, reflecting a year-on-year increase of 9.47%, while the net profit attributable to shareholders decreased by 12.88% to 633 million yuan [2][6]. - The second quarter of 2025 showed a revenue of 1.793 billion yuan, up 10.7% quarter-on-quarter, with a net profit of 388 million yuan, down 5.13% [2][6]. - The company continues to lead in the domestic market with 107 blood plasma collection stations, achieving a collection volume of 1,361 tons, maintaining a market share of approximately 20% [4]. Financial Performance - The company achieved a gross margin of 45.4% in the first half of 2025, down 10.3 percentage points year-on-year, and a net profit margin of 20.3%, down 5.2 percentage points [6]. - For the second quarter of 2025, the gross margin was 45.1%, and the net profit margin was 21.7% [6]. - The company has maintained effective control over various expense ratios, with sales, management, R&D, and financial expense ratios reported at 1.94%, 7.49%, 1.83%, and -0.03% respectively for the first half of 2025 [6]. Product Performance - The company’s albumin product line generated revenue of 1.345 billion yuan, up 20.8%, while the immunoglobulin product line achieved revenue of 1.427 billion yuan, up 6.6% [3]. - Other blood products saw a revenue decline of 13.2% to 328 million yuan, with a gross margin of 43.29%, down 14.78 percentage points [3]. Research and Development - The company continues to invest heavily in R&D, with new products expected to drive steady growth. Notable developments include the approval of a new 10% concentration immunoglobulin product and ongoing clinical trials for several other products [5]. Profit Forecast and Investment Suggestion - The forecast for net profit attributable to shareholders is 1.51 billion yuan for 2025, 1.76 billion yuan for 2026, and 2.08 billion yuan for 2027, with corresponding price-to-earnings ratios of 27, 23, and 20 times [6][11]. - The company is recognized as a leader in the blood products industry, with strong capabilities in plasma station acquisition and integration, alongside ongoing product development [6].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [20]. Core Insights - The company reported a revenue of 1.57 billion yuan for H1 2025, reflecting a year-on-year increase of 12.8%. However, the net profit attributable to shareholders decreased by 29% to 90 million yuan [2][3]. - The company's export sales showed robust growth, with H1 export revenue reaching 1.37 billion yuan, up 14.1% year-on-year. Despite some short-term disruptions in the supply chain, the overall export performance remained strong [3]. - The company's profitability was temporarily pressured by capacity transfer and exchange rate fluctuations, with a gross margin of 28.7%, down 1 percentage point year-on-year [4]. Financial Performance Summary - For 2025, the company is projected to achieve a net profit of 270 million yuan, with a growth rate of -5.4%. The expected net profits for 2026 and 2027 are 310 million yuan and 350 million yuan, respectively, with growth rates of 13.6% and 13.7% [4][5]. - The company's revenue is forecasted to grow from 3.33 billion yuan in 2024 to 4.73 billion yuan in 2027, with a compound annual growth rate of approximately 13% [5][12]. - The earnings per share (EPS) is expected to be 0.58 yuan in 2025, with a price-to-earnings (P/E) ratio of 15 [5][12]. Market Position and Strategy - The company is positioned as a leading manufacturer of thermal cups, leveraging its overseas production capacity to enhance competitive advantages. The establishment of a Thai factory has contributed to its revenue growth [3][4]. - The company aims to strengthen its domestic brand presence by elevating thermal cups from mere "drinking vessels" to "lifestyle carriers," tapping into the trend of domestic premium products [3].